Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, announced that it has established, in collaboration with A.forall Development NV, a wholly owned subsidiary of Boston-based private equity company The Riverside Company, and with IMGA Futurum Tech Fund, a fund managed by IMGA, the largest asset management firm in Portugal, a new company, named BRAFMed, to progress the clinical development and future outlicensing of Nanoencorafenib, a patient-centric nanoformulation of encorafenib. The signing of a Letter of Intent with respect to BRAFMed was first announced by Nanoform on May 20th, 2025.
Encorafenib, sold under the brand name Braftovi, a registered trademark of Pfizer, is an orally administered anti-cancer medication. Nanoform has developed a prototype nanoformulation with significantly higher drugload. If successful, the nanoformed product would offer greatly improved dosing over that of the marketed formulation, which requires a dosing regimen of up to six 75mg capsules taken daily. Clinical development and manufacturing of nanoformed drug substances for evaluation will take place at Nanoform’s development and manufacturing facility in Helsinki.
“Nanoform’s performance-enhancing technologies play a significant part in the development of new and improved medicines, and we are proud today to announce partnering the clinical development and commercialization of Nanoencorafenib, which is one of our innovative development initiatives,” said Prof. Edward Hæggström, CEO of Nanoform. “This announcement underscores investors’ and industry players’ confidence in our technologies and we are pleased to welcome these highly experienced partners to drive this improved product forward.”
“Our mission is to develop medicines that make a meaningful difference for patients. By combining our skills in development, registration, and commercialization with Nanoform’s pioneering technology and unique medicines such as nanoencorafenib, we can offer treatments that improve care and outcomes. Together, we’re committed to giving patients hope and better health through innovation”, said Steen Vangsgaard, CEO of A.forall Group NV.
“IMGA is proud to support the development of Nanoencorafenib alongside Nanoform and A.forall. We believe that Nanoform’s advanced nanoforming technology represents a significant leap forward in patient-centric drug innovation. By enabling higher drug loads and more convenient dosing, this technology has the potential to transform treatment experiences and outcomes for patients. Our investment reflects our commitment to fostering breakthrough solutions in healthcare and bringing meaningful improvements to those who need them most,” said Tiago Geraldes, private equity director at IMGA.
As announced by Nanoform on May 20, 2025, Nanoform will continue to support development of Nanoencorafenib with its nanoforming services and has granted an exclusive license to BRAFMed for Nanoform’s intellectual property covering Nanoencorafenib. Under the agreement, BRAFMed will pay Nanoform service fees, low single million development milestones, and up-to-mid-single digit tiered %-royalty. The BRAFMed partners’ target is to ultimately outlicense Nanoencorafenib as an attractive patient-centric lifecycle management opportunity or a value-added generic medicine. With the completion of the total investment now signed, Nanoform’s fully diluted ownership in BRAFMed is expected to be 40-50%. The investment is expected to be sufficient to finance the clinical development of Nanoencorafenib up and until its commercialization.
